TScan Therapeutics Inc.

NASDAQ: TCRX · Real-Time Price · USD
1.82
0.01 (0.55%)
At close: Aug 15, 2025, 10:07 AM

TScan Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
2.82M 21.05M 13.54M 10.14M
Cost of Revenue
4.11M 88.15M 5.14M 3.33M
Gross Profit
2.82M -67.1M 8.4M 6.81M
Operating Income
-134.82M -93.46M -66.64M -48.64M
Interest Income
12.06M 8M 1.59M 16K
Pretax Income
-127.5M -89.22M -66.22M -48.63M
Net Income
-127.5M -89.22M -65.81M -48.63M
Selling & General & Admin
29.56M 26.35M 20.35M 13.83M
Research & Development
107.35M 88.15M 59.82M 44.95M
Other Expenses
728K n/a 1.59M 16K
Operating Expenses
137.64M 114.51M 80.17M 58.78M
Interest Expense
3.65M 3.76M 1.18M n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
137.64M 114.51M 80.17M 58.78M
Income Tax Expense
n/a n/a -415K n/a
Shares Outstanding (Basic)
111.99M 65.6M 24.05M 23.91M
Shares Outstanding (Diluted)
111.99M 65.6M 24.05M 23.91M
EPS (Basic)
-1.14 -1.36 -2.74 -2.03
EPS (Diluted)
-1.14 -1.36 -2.74 -2.03
EBITDA
-119.74M -80.1M -59.91M -45.3M
EBIT
-123.85M -85.46M -65.05M -48.63M
Depreciation & Amortization
4.11M 5.36M 5.14M 3.33M